VTRO (Vitro Biopharma) Total Current Liabilities: $2.54 Mil (As of Oct. 2022)


What is Vitro Biopharma Total Current Liabilities?

Vitro Biopharma VTRO Total Current Liabilities is $2.54 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Vitro Biopharma's total current liabilities for the quarter that ended in Oct. 2022 was $2.54

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Vitro Biopharma Total Current Liabilities Related Terms

Vitro Biopharma Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Total Current Liabilities Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 2.50 0.12 1.42 2.54

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.27 2.50 0.12 1.42 2.54

Vitro Biopharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Vitro Biopharma's Total Current Liabilities for the fiscal year that ended in Oct. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.777+0.113
+Other Current Liabilities+Current Deferred Liabilities
=0+0.65
=2.54

Vitro Biopharma's Total Current Liabilities for the quarter that ended in Oct. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.777+0.113
+Other Current Liabilities+Current Deferred Liabilities
=0+0.65
=2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $2.54 Mil mean?
Vitro Biopharma (VTRO) has a Total Current Liabilities of $2.54 Mil as of Oct. 2022. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Vitro Biopharma and its competitors.
Is Vitro Biopharma's Total Current Liabilities too high?
Vitro Biopharma's current Total Current Liabilities is $2.54 Mil.
How does Vitro Biopharma's Total Current Liabilities compare to ?
Vitro Biopharma's Total Current Liabilities of $2.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Vitro Biopharma and its competitors. Vitro Biopharma's current Total Current Liabilities is $2.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Total Current Liabilities of $2.54 Mil. The current Total Current Liabilities is $2.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Total Current Liabilities is $2.54 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.